Table 1. Baseline Sociodemographic and Clinical Characteristics of Patients Included in the Study.
| Characteristic | Patients, No. (%) | |||
|---|---|---|---|---|
| DOAC (n = 2152) | LMWH (n = 1488) | Warfarin (n = 1460) | Total (N = 5100) | |
| Age, mean (SD), y | 67.4 (12.1) | 63.4 (12.8) | 67.6 (11.6) | 66.3 (12.3) |
| Gender | ||||
| Women | 1129 (52.5) | 792 (53.2) | 749 (51.3) | 2670 (52.4) |
| Men | 1023 (47.5) | 696 (46.8) | 711 (48.7) | 2430 (47.6) |
| Race | ||||
| Asian | 48 (2.2) | 36 (2.4) | 23 (1.6) | 107 (2.1) |
| Black | 350 (16.3) | 211 (14.2) | 238 (16.3) | 799 (15.7) |
| Hispanic | 168 (7.8) | 127 (8.5) | 94 (6.4) | 389 (7.6) |
| White | 1458 (67.8) | 1053 (70.8) | 1048 (71.8) | 3559 (69.8) |
| Unknown | 128 (5.9) | 61 (4.1) | 57 (3.9) | 246 (4.8) |
| Cancer type | ||||
| Lung | 351 (16.3) | 285 (19.2) | 277 (19.0) | 913 (17.9) |
| Urologic | 375 (17.4) | 167 (11.2) | 288 (19.7) | 830 (16.3) |
| Breast | 352 (16.4) | 144 (9.7) | 203 (13.9) | 699 (13.7) |
| Colorectal | 251 (11.7) | 138 (9.3) | 191 (13.1) | 580 (11.4) |
| Hematological | 262 (12.2) | 125 (8.4) | 149 (10.2) | 536 (10.5) |
| Gynecological | 132 (6.1) | 170 (11.4) | 107 (7.3) | 409 (8.0) |
| Pancreaticobiliary | 127 (5.9) | 188 (12.6) | 86 (5.9) | 401 (7.9) |
| Upper gastrointestinal | 86 (4.0) | 118 (7.9) | 69 (4.7) | 273 (5.4) |
| Brain | 80 (3.7) | 96 (6.5) | 51 (3.5) | 227 (4.5) |
| ENT | 90 (4.2) | 48 (3.2) | 33 (2.3) | 171 (3.4) |
| Musculoskeletal | 32 (1.5) | 32 (2.2) | 20 (1.4) | 84 (1.6) |
| Cancer of unknown primary | 41 (1.9) | 20 (1.3) | 13 (0.9) | 74 (1.5) |
| Genitourinary | <11 (0.4)a | <11 (0.3)a | <11 (0.2)a | >11 (0.3)a |
| Other | <11 (0.1)a | <11 (0.1)a | <11 (0.1)a | <11 (0.1)a |
| Metastatic solid tumor | 1164 (54.1) | 1104 (74.2) | 795 (54.5) | 3063 (60.1) |
| Baseline chemotherapy within 6 mo before index date | 1126 (52.3) | 920 (61.8) | 741 (50.8) | 2787 (54.6) |
| Surgery within 6 mo before index date | 775 (36.0) | 557 (37.4) | 640 (43.8) | 1972 (38.7) |
| VTE type | ||||
| DVT | 1033 (48.0) | 663 (44.6) | 709 (48.6) | 2405 (47.2) |
| PE | 953 (44.3) | 677 (45.5) | 624 (42.7) | 2254 (44.2) |
| DVT and PE | 166 (7.7) | 148 (9.9) | 127 (8.7) | 441 (8.6) |
| VTE visit type | ||||
| Hospitalization | 1263 (58.7) | 1003 (67.4) | 1090 (74.7) | 3356 (65.8) |
| ED | 709 (32.9) | 382 (25.7) | 266 (18.2) | 1357 (26.6) |
| Office | 180 (8.4) | 103 (6.9) | 104 (7.1) | 387 (7.6) |
| VTE risk scoreb | ||||
| 1 | 1098 (51.0) | 556 (37.4) | 690 (47.3) | 2344 (46.0) |
| 2 | 683 (31.7) | 488 (32.8) | 510 (34.9) | 1681 (33.0) |
| 3 | 371 (17.2) | 444 (29.8) | 260 (17.8) | 1075 (21.1) |
| Charlson Comorbidity Index | ||||
| Mean (SD) | 7.6 (3.8) | 8.6 (3.2) | 7.6 (3.7) | 7.9 (3.6) |
Abbreviations: DOAC, direct oral anticoagulants; DVT, deep vein thrombosis; ED, emergency department; ENT, ear, nose, and throat; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism.
a
Number of patients masked to protect confidentiality.
b
VTE risk was determined by cancer type (eTable 1 in Supplement 1). Risk score of 1 indicates low risk of VTE; 2, intermediate; and 3, high.